Cellares
Company Headquarters: 345 Allerton Ave
South San Francisco, CA 94080
E: bd@cellares.com
W: https://www.cellares.com/(Hubspot Tracked URL)
LinkedIn: https://www.linkedin.com/company/cellares-corporation
Unlock the Full Potential of Your Cell Therapy With Cellares
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies that accelerate access to life-saving cell therapies.
Cellares’ flagship technologies—the Cell Shuttle™, an automated manufacturing platform, and Cell Q™, an automated quality control system— will power a global network of Smart Factories that can produce up to 10x more therapies and reduce batch prices by up to 50% compared to conventional CDMOs.
Partnering with Cellares enables early-stage cell therapy developers the advantages of immediate, small-volume economies of scale, while providing those with commercially approved therapies the capacity required to meet the total global patient demand for their life-saving medicines.
The company is headquartered in South San Francisco, California, with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing.
Purpose-Built Technology to Power Your Program
Cellares’ Cell Shuttle™, leveraging fully-closed proprietary consumable cartridges, integrates all the technologies required to manufacture the majority of suspension-based cell therapies in a flexible and high-throughput platform that delivers end-to-end automation. The Cell Shuttle’s ability to manufacture 16 doses in parallel means every run delivers life-saving cell therapies at previously unrealized scales.
While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ integrates best-in-class, off-the-shelf instrumentation to automate both in-process analysis and final product release quality control testing.
Cell Shuttles and Cell Qs will be deployed in Cellares’ Smart Factories around the world, enabling each Smart Factory to produce up to 10 times as many cell therapy batches as conventional CDMOs with the same facility size and headcount, while providing batch price reductions of up to 50%.
The system is an FDA-designated Advanced Manufacturing Technology. As a result of this designation, developers leveraging Cellares’ IDMO Manufacturing services will receive expedited FDA review, leading to decreased times to IND and BLA.
See How Our Technologies Work Together
A Smarter Way to Scale Cell Therapies
Cellares is overcoming the limitations of conventional CDMOs, mitigating risks, and simplifying your cell therapies’ journey to patients.
With the Cellares manufacturing model, you reserve only the capacity that you need and pay no clean room fees during clinical manufacture. Manufacturing reservation fees are aligned with your cell therapy’s success and cash flow, providing you with the flexibility to scale as your demand grows.
Partnering with Cellares provides you with up to 50% lower batch prices compared to conventional CDMOs, even at low batch volumes, allowing you to break even on initial tech translation costs after just ~28 batches. This efficiency translates into a ~10x return on initial investment by the completion of Phases 1, 2, and 3, ultimately extending your runway by up to two years.
Translate and automate your existing process in as little as 6 months, accelerating your path to IND and BLA filing. Our comprehensive support includes full process development, analytical development, and regulatory services to optimize your journey from beginning to end.
Software-defined manufacturing eliminates lengthy hardware changes and provides a seamless pathway to scale up. It makes transferring your process from one IDMO Smart Factory to another as simple as the click of a button, enabling rapid global expansion.
Additionally, as a user of an FDA Advanced Manufacturing Technology-designated system, you’ll benefit from expedited regulatory review, creating a streamlined pathway to approval.
Posted Date: 6/9/2025
This record has been viewed 17 times.